3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow IONIS-ANGPTL3-LRx: new trials by email Literature Review of IONIS-ANGPTL3-LRx trials Research Report on IONIS-ANGPTL3-LRx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg - NAFLD, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Akcea Therapeutics | 105 | 2017-12-21 | 2021-02-01 |
| Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia IONIS ANGPTL3-LRx, Placebo - Hypertriglyceridemia, Familial Hypercholesterolemia | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 48 | 2015-11-30 | 2020-11-19 |
Hypertriglyceridemia (2) · Metabolic Diseases (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Digestive System Diseases (1) · Dyslipidemias (1) · Endocrine System Diseases (1) · Familial hyperchylomicronemia syndrome (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type I (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemias (1)
Akcea Therapeutics (2) · Ionis Pharmaceuticals, Inc. (1)
Canada (3) · United States (1)
2015 (1)